Enzyme/Receptor Inhibitors
Overview:
A9 Biopharma specializes in the discovery and development of small-molecule enzyme inhibitors and receptor antagonists across multiple therapeutic areas. Our expertise spans kinases, proteases, GPCRs, nuclear receptors, and other validated drug targets, enabling tailored solutions for complex disease pathways.
Capabilities:
- Early discovery to lead optimization support
- Structure–Activity Relationship (SAR) studies
- Scaffold modification and route optimization
- Enhanced potency, selectivity, and physicochemical properties
- Full analytical characterization and scalable synthesis
Benefits:
- Accelerate therapeutic development
- Reliable, high-quality compounds for preclinical and clinical studies
- Customized solutions aligned with your target profile